Patent application number | Description | Published |
20090326206 | Single-chain Multiple Antigen-binding Molecule, Its Preparation and Use - The present invention relates to a single-chain, multiple antigen-binding molecule with diverse variable domains of a heavy and of a light chain of an immunoglobulin, which are connected in the form of a VH-VL construct, which are in turn connected together via a peptide, and to the preparation and use thereof as pharmaceutical or diagnostic aid. | 12-31-2009 |
20100150916 | huTNFR1 Selective Antagonists - The present invention relates to a ligand which specifically binds to the human tumor necrosis factor type 1 receptor (huTNFR1), the ligand comprising one or more amino acid sequences of human origin capable of reducing the immunogenic response of the ligand in human beings and one or more amino acid sequences capable of selectively binding to huTNFR1. The present invention further relates to a nucleic acid encoding said ligand and to a pharmaceutical composition for the treatment of disorders connected to huTNFR1. | 06-17-2010 |
20130244341 | huTNFR1 SELECTIVE ANTAGONISTS - The present invention relates to a ligand, which specifically binds to human tumor necrosis factor type 1 receptor (huTNFR1). The ligand includes one or more amino acid sequences of human origin capable of reducing the immunogenic response of the ligand in humans and one or more amino acid sequences capable of selectively binding to huTNFR1. The present invention also relates to a nucleic acid sequence encoding the ligand and to a pharmaceutical composition for the treatment of disorders related to huTNFR1. | 09-19-2013 |